Updated Instructions: Seeking Proposals: Antibacterial Accelerator Broad Agency Announcement Special Instructions

About Image

In 2016, BARDA partnered with international funders to launch what would become the world’s largest early-stage research and development accelerator for new antibacterial products. The goal was to build a diverse, early-stage development portfolio of innovative products to treat, prevent, and diagnose antibiotic-resistant infections.

The five-year program has exceeded the targets set out in the 2015-2020 U.S. National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB) (PDF - 519KB), supporting over 90 projects with 62 active within the portfolio, leading to nine first-in-human clinical studies. BARDA’s $180 million investment in the accelerator was met with an additional $300 million in funding and in-kind services from other donors, and over $1.94 billion in follow-on private sector investment in product developers.

As the initial five-year program comes to a close, the 2020-2025 U.S. National Action Plan for CARB spells out the U.S. government’s commitment to continued support of early-stage development of innovative antibacterial products. Demonstrating that ongoing commitment, today we are launching a set of special instructions to the BARDA Broad Agency Announcement (BAA) to seek proposals for another 10 years of investment through an Antibacterial Accelerator.

This program will continue to be a platform for global partnerships, built on lessons learned over the last five years, to spur innovation and expand the pipeline of early-stage antibacterial candidates. With continued focus on supporting candidate programs to counter the threat of antimicrobial resistance now and in the future, the Antibacterial Accelerator will provide non-dilutive funding and a full suite of research and development support to product developers worldwide.


For more details, check out the updated BARDA BAA Amendment #26, Special Instructions Issuance for the Area of Interest #3.4 Antibacterial Accelerator of the BARDA BAA (BAA-18-100-SOL-00003).

Full proposals may be submitted until 4:30PM ET on Monday, June 28, 2021.

Inquiries for BARDA BAA-18-100-SOL-00003 Amendment #25, Special Instructions for Area of Interest #3.4 Antibacterial Accelerator were collected from May 12, 2021, through May 19, 2021. Responses to inquiries are available here.



For more details, check out the BARDA BAA Amendment #25, Special Instructions Issuance for the Area of Interest #3.4 Antibacterial Accelerator of the BARDA BAA (BAA-18-100-SOL-00003).

Full proposals may be submitted until 4:30PM ET on Monday, June 28, 2021.

BARDA will also provide written responses to inquires received by 4:30PM ET on Wednesday, May 19, 2021.

Last Updated: June 14, 2021
Website Refresh - www.medicalcountermeasures.gov is pleased to announce a phased launch of our newly redesigned public website. We are making website improvements to provide a more modern and customer-centric web experience. Over the next several months you will see differences throughout the site while we continue implementing updates. Thank you for your understanding and please let us know if you have any questions: techwatchinbox@hhs.gov